Ran Hener
Pancreatic Ductal Adenocarcinoma (PDAC) stands as one of the most lethal forms of cancer with limited treatment options and poor prognosis. The hallmark of PDAC is its resistance to conventional therapies, urging the exploration of targeted therapeutic approaches. In recent years, significant progress has been made in understanding the oncogenic pathways driving PDAC development and progression. This article provides an overview of the clinical and preclinical strategies targeting these pathways, offering insights into promising avenues for the treatment of this deadly cancer.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 